Hanmi

^LAPSGlucagon Combo is a novel drug candidate consisting of HM15136 (^LAPSGlucagon analog) and efpeglenatide (^LAPSExd4 analog). Although the efficacy of glucagon-like protein-1 receptor agonist (GLP-1RA) is well-established for obesity and T2DM, more efforts are still required to close the efficacy gap with bariatric surgery. Recent advances demonstrate the beneficial effects of glucagon (GCG) receptor activation on energy expenditure, lipid metabolism, and cardiorenal protection in addition to satiety control. Therefore, combination of GCG and GLP-1 not only enhances body weight loss barely achieved by current therapies, but also expands its therapeutic utilities to various cardio-metabolic diseases.

In nonclinical studies, therapeutic benefits of ^LAPSGlucagon Combo were well demonstrated in animal models of obesity, dyslipidemia, NASH/fibrosis, or chronic kidney disease. In addition to GLP toxicology package for each mono, repeat-dose toxicology studies of ^LAPSGlucagon Combo were completed to support its seamless clinical development. Based on these results, Hanmi expect that by optimizing the composition between HM15136 and efpeglenatide, ^LAPSGlucagon Combo could be a next-generation anti-obesity medication with the differentiated CVRM (cardiovascular, renal and metabolism) benefits.

• Easy to co-formulate with variable molar ratio
• Confirmed no drug-to-drug interaction (non-clinical)
• Ratio suitably optimized for diverse indications

• Extended duration of action by LAPSCOVERY
• Targeting first-in-class weekly GLP-1 and GCG co-formulation

Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders (657-P)
Poster, American diabetes association (ADA) 81st Scientific sessions, 2021